These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 15379708)

  • 1. Advances in insulin sensitizers.
    Lohray BB; Bhushan V
    Curr Med Chem; 2004 Sep; 11(18):2467-503. PubMed ID: 15379708
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thiazolidinediones as antidiabetic agents: A critical review.
    Nanjan MJ; Mohammed M; Prashantha Kumar BR; Chandrasekar MJN
    Bioorg Chem; 2018 Apr; 77():548-567. PubMed ID: 29475164
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peroxisome proliferator activated receptor ligands for the treatment of insulin resistance.
    Patsouris D; Müller M; Kersten S
    Curr Opin Investig Drugs; 2004 Oct; 5(10):1045-50. PubMed ID: 15535425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Troglitazone and related compounds: therapeutic potential beyond diabetes.
    Fujiwara T; Horikoshi H
    Life Sci; 2000 Oct; 67(20):2405-16. PubMed ID: 11065164
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Against insulin resistance. Insulin sensitizers].
    Verspohl EJ; Weiland F
    Pharm Unserer Zeit; 2002; 31(3):280-92. PubMed ID: 12071125
    [No Abstract]   [Full Text] [Related]  

  • 6. [Non-agonist inhibitors of Cdk5-dependent phosphorylation of PPAR as insulin sensitizers in the future?].
    Merk D; Schubert-Zsilavecz M
    Pharm Unserer Zeit; 2012 May; 41(3):182-3. PubMed ID: 22844662
    [No Abstract]   [Full Text] [Related]  

  • 7. Cardiovascular effects of insulin sensitizers in diabetes.
    Jawa A; Fonseca V
    Curr Opin Investig Drugs; 2006 Sep; 7(9):806-14. PubMed ID: 17002258
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insulin resistance and PPAR insulin sensitizers.
    Bhatia V; Viswanathan P
    Curr Opin Investig Drugs; 2006 Oct; 7(10):891-7. PubMed ID: 17086933
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of PPARs in the microvascular dysfunction in diabetes.
    Vinik A; Parson H; Ullal J
    Vascul Pharmacol; 2006 Jul; 45(1):54-64. PubMed ID: 16784897
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Muraglitazar, a novel dual (alpha/gamma) peroxisome proliferator-activated receptor activator, improves diabetes and other metabolic abnormalities and preserves beta-cell function in db/db mice.
    Harrity T; Farrelly D; Tieman A; Chu C; Kunselman L; Gu L; Ponticiello R; Cap M; Qu F; Shao C; Wang W; Zhang H; Fenderson W; Chen S; Devasthale P; Jeon Y; Seethala R; Yang WP; Ren J; Zhou M; Ryono D; Biller S; Mookhtiar KA; Wetterau J; Gregg R; Cheng PT; Hariharan N
    Diabetes; 2006 Jan; 55(1):240-8. PubMed ID: 16380499
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vitamin E tocotrienols improve insulin sensitivity through activating peroxisome proliferator-activated receptors.
    Fang F; Kang Z; Wong C
    Mol Nutr Food Res; 2010 Mar; 54(3):345-52. PubMed ID: 19866471
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug evaluation: rivoglitazone, a new oral therapy for the treatment of type 2 diabetes.
    Schimke K; Davis TM
    Curr Opin Investig Drugs; 2007 Apr; 8(4):338-44. PubMed ID: 17458185
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New therapeutic agents for the treatment of NIDDM.
    Kuehnle HF
    Exp Clin Endocrinol Diabetes; 1996; 104(2):93-101. PubMed ID: 8740931
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current views on the mechanism of action of thiazolidinedione insulin sensitizers.
    Goldstein BJ
    Diabetes Technol Ther; 1999; 1(3):267-75. PubMed ID: 11475273
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis and biological activity evaluation of a new class of 2,4-thiazolidinedione compounds as insulin enhancers.
    Huiying Z; Guangying C; Shiyang Z
    J Enzyme Inhib Med Chem; 2019 Dec; 34(1):981-989. PubMed ID: 31072232
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective PPAR agonists for the treatment of type 2 diabetes.
    Nehlin JO; Mogensen JP; Petterson I; Jeppesen L; Fleckner J; Wulff EM; Sauerberg P
    Ann N Y Acad Sci; 2006 May; 1067():448-53. PubMed ID: 16804025
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Editorial: Natural Compounds and Their Derivatives as a Source of Promising Drugs for Diabetes and Insulin Resistance.
    Mena Barreto Silva FR; Silva Frederico MJ
    Curr Drug Targets; 2017; 18(6):618. PubMed ID: 28831919
    [No Abstract]   [Full Text] [Related]  

  • 18. Pharmacological treatment of insulin resistance in obesity.
    Camejo G; Ljung B; Oakes N
    Nutr Metab Cardiovasc Dis; 2001 Aug; 11(4):275-84. PubMed ID: 11831112
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical difference between thiazolidinediones and biguanides].
    Hotta N
    Nihon Rinsho; 2001 Nov; 59(11):2219-27. PubMed ID: 11712411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preventing the progression of diabetes mellitus.
    Reamy BV
    Am Fam Physician; 2005 Feb; 71(3):425. PubMed ID: 15712615
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.